Belgian biotech UCB has made its second acquisition of the year, buying T-cell engager player Candid Therapeutics for up to $2.2 billion.

Ken Song has done it again. The biopharma veteran’s all-out effort to prove T cell engagers’ potential in autoimmune diseases is getting picked up by

In another setback for abortion care in the US, an appeals court has issued an order restricting the distribution of mifepristone through the mail.

Welcome back to Endpoints Weekly! The last week of April brought a downpour of news as several pharma companies reported their first-quarter earnings. Max Gelman

Moderna said it’s working with US regulators to provide post-marketing data on its Covid-19 vaccines that could restore their use to a wider group after